Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Opioid Analgesics Sales to Grow by 1.7X through 2031 as the Demand for Post-Surgery Pain Management Continues to Rise

Future Market Insights’ (FMI’s) latest survey provides an unbiased analysis of the opioid analgesics market, presenting historical demand data (2016-2020) and forecast statistics for the period (2021-2031). It also examines the demand outlook of the market in terms of drug class, indication, route of administration, end user, and region over the coming decade.

As per an exhaustive study by FMI, the Global Opioid Analgesics Market is anticipated to reach US$ 65.8 billion by 2031. In response to surging demand for post-surgery pain management and focus on novel drug formulations for analgesics, the market is estimated to expand at a CAGR of 5.4% over the forecast period 2021-2031, in comparison to the 4.2% CAGR registered from 2106 to 2020.

Opioid analgesics market is largely driven by the increasing prevalence of chronic disorders, neuropathic pain, and orthopedic diseases. Opioids are extensively used for anesthesia, cough suppression, cancer pain management, and treatment of several other conditions. In addition to this, the development of novel analgesics with fewer side effects is expected to spur sales by 1.7X through 2031.

A considerable rise in the number of surgical procedures has been reported in the last few years. According to the International Society of Aesthetic Plastic Surgery (ISAPS), around 11.3 million surgeries were reported across the world in 2019. As opioids are used as medications for managing and reducing pain post-surgeries, the surgical pain indication segment is anticipated to account for nearly 45.9% of the total sales by 2031.

Request a report sample to gain comprehensive insights at


As per FMI, Europe is projected to account for a considerable share in the global market, exhibiting sales growth at a CAGR of 5.4% between 2021 and 2031. The growth in the region is attributed to the increasing prevalence of chronic diseases and presence of favorable medical reimbursement policies in the U.K and Germany.

“Commercialization of non-abusive opioids and increasing availability of opioid analgesics through online distribution channels are expected to accelerate the sales of opioid analgesics,” says the FMI analyst.

Key Takeaways from Opioid Analgesics Market Study

  • The U.S. is anticipated to lead the market in North America, accounting for nearly 86% of the overall sales in 2021.
  • Sales of opioid analgesics in Germany are estimated to total US$ 2.2 billion, growing at a CAGR of 3.8% during the assessment period.
  • The market in India is forecast to account for 35.4% of the sales in South Asia, expanding at a CAGR of 5.7% between 2021 and 2031.
  • China is expected to emerge as the most lucrative market for opioid analgesics in East Asia, contributing around 54.2% of the sales revenue in the region by 2021 end.
  • Among drug class verticals, oxycodone is estimated to dominate the segment accounting for more than 19% of the global demand in 2021.


Key Drivers

  • Surging demand for facial and body aesthetics in response to the rising number of aesthetic surgical procedures such as breast implantation, eyelid surgeries, and abdominoplasty conducted worldwide will spur the sales across surgical pain segment.
  • Increasing adoption of opioid maintenance treatment (OMT) for treating opioid dependence (OD) across Germany, the U.K., the U.S., and others are anticipated to drive the market growth.


Key Restraints

  • Side effects associated with opioid analgesics such as drowsiness, nausea, constipation, clouded thinking, and psychological & physical addiction are hampering the market growth.
  • Stringent government regulation and guidelines regarding manufacturing, storage, marketing, and selling of opioid products are restraining the growth of opioid analgesics.


Discover more about the opioid analgesics analysis with figures and data tables, along with the table of contents. https://www.futuremarketinsights.com/ask-question/rep-gb-14043

Competitive Landscape

Leading manufacturers are emphasizing on launching new and revised products to enhance their product portfolios. Strategies such as product approvals, partnerships, agreements, merger, facility expansion, and collaborations are expected to assist market players strengthen their footprint and gain a competitive edge over other players. For instance,

  • In May 2020, Assertio Therapeutics, Inc., an American specialty pharmaceutical company, announced entering into merger agreement with a U.S.-based pharmaceutical company, Zyla Life Sciences. The merger will assist companies to expand their product portfolio of inflammation, neurology, and chronic pain medications.


  • In September 2018, Novartis, a Swiss multinational pharmaceutical corporation, announced signing an agreement for marketing, distribution, and sales, of well-known pain medicine brands such as Cataflam (diclofenac potassium) and Voltaren (diclofenac sodium) in Thailand, Malaysia and Philippines.


  • Pfizer Inc.
  • Abbott Laboratories
  • Janssen Pharmaceuticals, Inc. [Johnson & Johnson]
  • Novartis AG
  • Bayer AG
  • GlaxoSmithKline plc
  • F. Hoffmann-La Roche AG,
  • Boehringer Ingelheim International GmbH
  • Bausch Health Companies Inc.
  • Sanofi S.A.
  • Teva Pharmaceuticals
  • AbbVie Inc. (Allergan plc)
  • Purdue Pharmaceuticals L.P.
  • Sun Pharmaceutical Industries Ltd.
  • Mallinckrodt Pharmaceuticals
  • Endo Pharmaceuticals Inc. [Endo International plc]
  • Assertio Therapeutics, Inc. [Assertio Holdings, Inc.]

More Valuable Insights on Opioid Analgesics Market

FMI, in its new report, offers an unbiased analysis of the global opioid analgesics market, analyzing forecast statistics through 2021 and beyond. The survey reveals growth projections on in opioid analgesics market with detailed segmentation:

Get customized report as per your requirement – https://www.futuremarketinsights.com/customization-available/rep-gb-14043

 Key Questions Covered in the Report

  • The report offers insight into opioid analgesics market demand outlook for the forecast period 2021-2031
  • The market study also highlights projected sales growth for opioid analgesics market between 2021 and 2031
  • Opioid analgesics market survey identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry
  • Opioid analgesics market share analysis, covering key companies within the industry and coverage of strategies such as mergers & acquisitions, joint ventures, collaborations or partnerships, and others